All News

Preliminary results from part 2 of the phase 2 trial evaluating VP-315 in basal cell carcinoma found no dose-limiting toxicities or treatment-related serious adverse events.

The addition of neoadjuvant S-1 also reduced the risk of death compared with adjuvant therapy alone in the phase 3 PRODIGY trial.

The PREFERABLE-EFFECT study found that supervised resistance and aerobic exercise were associated with reduced fatigue in patients with metastatic breast cancer.

Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.

Phase 1/2 data support the fast track designation for BGB-16673 as a therapy for patients with relapsed/refractory chronic lymphocytic leukemia.

Findings from the phase 3 MARIPOSA-2 trial were the subject of a recent discussion of ambivantamab plus chemotherapy with or without lazertinib in EGFR-mutated NSCLC.

The European Commission’s decision represents the first regulatory approval of odronextamab for patients with follicular lymphoma or DLBCL.

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Minimal residual disease as an end point in multiple myeloma has been widely discussed and was even a topic of a recent ODAC meeting.

Experts in multiple myeloma sat down to discuss the use of bispecific antibodies and their impact in the space.

Supporting data for the designation comes from the ARTEMIS-001 trial evaluating preliminary safety and antitumor activity of GSK’227 in solid tumors.

PAX8, a marker for aggressive disease in numerous cancer types, was more highly expressed in Black patients with uterine serous carcinoma.

Investigators are evaluating the efficacy and safety of APG-157 for patients with head and neck cancer in a phase 2 clinical trial.

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Brentuximab vedotin plus chemotherapy significantly improved HRQOL in both pediatric and young adult patients with high-risk Hodgkin lymphoma.

Phase 2 data support the National Medical Products Administration’s approval of fulzerasib for those with KRAS G12C–mutated NSCLC in China.

The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.

Neil M. Iyengar, MD, highlights how to best integrate exercise oncology into multidisciplinary care.

The FDA has set a Prescription Drug User Fee Act date of April 21, 2025, for the potential approval of frontline nivolumab/ipilimumab in unresectable HCC.

Krystal Preston, PharmD, BCPS, discussed the use and administration of tislelizumab for patients with resectable or metastatic esophageal squamous cell carcinoma.

Further development of vebreltinib in patients with MET fusions is being considered following results from the phase 2 SPARTA trial.

“The dMMR population, which are patients who have deficiency in their mismatch repair proteins, had the most pronounced impact in PFS, and we’re seeing that trend for prolonged periods of time; we may be curing many of these patients,” said Ritu Salani, MD.